Dublin, Aug. 28, 2020 (GLOBE NEWSWIRE) -- The "Coronavirus Disease 2019 (COVID-19) Impact on Immunology Trials - July 2020" report has been added to ResearchAndMarkets.com's offering.

Since the beginning of March 2020, clinical trial operations were most disrupted as a result of the COVID-19 pandemic. This report summarizes the impact on immunology patient, clinical trial logistics, and key opinion leader (KOL) insights on the long-term impact of the pandemic.

Report Scope

Reasons to Buy

Key Topics Covered

1 Immunology Trials Disrupted1.1 Overview of Immunology Trials Disrupted1.2 Regulatory Guidance Across the 8MM

2 KOL Insights: Continuity of Care

3 KOL Insights: Trial Logistics3.1 Recruitment3.2 Conduct in Isolation3.3 Supply Chain

4 KOL Insights: Trials Looking Forward4.1 Clinical Trials Disrupted Due to COVID4.2 Immunology Clinical Trials Resumed

5 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/5kx76f

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See more here:
Immunology Trials and COVID-19 - An Overview of Changes to Clinical Practices and Clinical Trial Logistics in H1, 2020 as a Result of the Pandemic -...